Prophylaxis of post-ERCP pancreatitis by the intravenous administration of the non-steroidal anti-inflammatory drug

Prophylaxis of post-ERCP pancreatitis by the intravenous administration of the non-steroidal anti-inflammatory drug - Intravenous flurbiprofen axetil for prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013193

Enrollment

400

Registered

2014-02-19

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-ERCP pancreatitis

Interventions

Intravenous administration of flurbiprofen axetil over 15 min from the start of ERCP No intravenous administration of flurbiprofen axetil over 15 min from the start of ERCP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent ERCP

Exclusion criteria

Exclusion criteria: The following patients were excluded: those with contraindications to flurbiprofen axetil, those who had taken any NSAID during the preceding week, those diagnosed with acute pancreatitis during the month before ERCP, those with an anticipated low risk of PEP (those with chronic calcific pancreatitis or a pancreatic head tumor or those undergoing routine biliary stent exchange), and those who did not agree to participate in the study.

Design outcomes

Primary

Measure	Time frame
The primary outcome is reduction in the rate of post-ERCP pancreatitis, defined as new upper abdominal pain and hyperamylasemia.	—

Secondary

Measure	Time frame
Secondary outcomes included prevention of increase in post-ERCP serum amylase levels and reduction in the severity of PEP.	—

Countries

Japan

Contacts

Public ContactShun Kobayashi

Nihon University School of Medicine Division of Gastroenterology and Hepatology, Department of Medicine,

kobayashi.shun@nihon-u.ac.jp03-3293-1711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026